Research record

Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT Phase 3.

Randomized human study published by EBioMedicine, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.

Plain-language guide

Five questions to ask about this record

What this is
randomized-human record from EBioMedicine.
Why it may matter
It matched a longevity topic and may show how that evidence area is developing.
Evidence
Automated topic match 100%; this is not a medical rating.
Main limitation
One research record does not prove safety, effectiveness, or usefulness for an individual.
What changed
Source metadata was published or refreshed July 4, 2020.
Where to verify
Open the primary source below for methods, population, results, and limitations.
Published
July 4, 2020
Journal
EBioMedicine
Authors
Markus Wolfien, Denise Klatt, Amankeldi A Salybekov, Masaaki Ii, Miki Komatsu-Horii, Ralf Gaebel, Julia Philippou-Massier, Eric Schrinner, Hiroshi Akimaru, Erika Akimaru, Robert David, Jens Garbade, Jan Gummert, Axel Haverich, Holger Hennig, Hiroto Iwasaki, Alexander Kaminski, Atsuhiko Kawamoto, Christian Klopsch, Johannes T Kowallick, Stefan Krebs, Julia Nesteruk, Hermann Reichenspurner, Christian Ritter, Christof Stamm, Ayumi Tani-Yokoyama, Helmut Blum, Olaf Wolkenhauer, Axel Schambach, Takayuki Asahara
DOI
10.1016/j.ebiom.2020.102862
Evidence class
randomized-human
Record status
published
Match confidence
100%
Source feed
PubMed
Automated source synopsis

Randomized human study published by EBioMedicine, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.

Evidence snapshot

What the source actually supports

Evidence stage
Randomized human study
Study design
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Evidence population
Human evidence
Participants
Not reported
Population
Not reported
Duration
Not reported
Intervention
Comparator
Not reported
Outcomes measured
Reported result
No reusable finding-level result is available in this record.

Main limitationBibliographic metadata identifies the record but does not provide enough reusable detail to summarize its population, comparison, findings, or effect size.

Safety and approvalThis index record does not establish safety, effectiveness, dose, or suitability for any person. A publication record is not a regulatory approval or treatment recommendation.

Source supportBibliographic citation metadata and controlled indexing terms only. Read the linked source for methods and results.

Evidence stage · randomized-humanThis describes the study type, not whether an intervention is safe or effective.
Lab or animalHuman studyRandomized trialEvidence synthesis
Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Senolytics · 70%Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
  • Stem cells · 100%Title contains controlled term: stem cell. Source terminology contains: stem cell. Title supplies longevity context: senescence. Study type is explicitly identified as Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial.

Automated source check 95% · update recency 50%. These figures help sort records; they are not medical ratings.

BibTeX · RIS

senolyticsstem cells
Read the original source →Export JSON